With an eye toward making a low-cost hepatitis C treatment available in numerous countries, a nonprofit says that a mid-stage study showed an experimental combination of two pills appeared safe and effective, while offering high cure rates for hard-to-treat patients.

The results were greeted with enthusiasm by patient advocacy groups, because once testing is completed, the nonprofit hopes to register the combination treatment in middle-income countries, starting with Malaysia, where it could be sold for $300, or about half the price of existing treatment in that country.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • May I observe, although it could be my ‘1st world bias,’ that cutting the price of a drug by 50% – from 600 USD to 300 USD doesn’t seem to be ‘breaking’ much? Especially when one considers Gilead helped arrange the 600 USD price …. down from the 84,000 USD cited in the post. (That price is after all a 99.3% reduction?!)

    • But Ed, you note that “The Gilead licensing arrangement also drew criticism because it excluded some middle-income countries, such as Malaysia” yet say that the 99%+ reduction in US cost for Malaysia is the doing of Gilead. Maybe the authorized generics are cheaper, though no mention is made of what these cost. Nevertheless, when you give a 99%+ discount and it’s not enough, you’re essentially asking that it be made for free. Sorry, but pharmaceuticals are an engine of amazing medical progress and I’m tired of the US carrying the cost of that for the rest of the world, including those who actually could pay for it but still impose cost controls.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy